Pharmacy, American Hospital of Paris, Neuilly-sur-Seine, France
Pharmacy, American Hospital of Paris, Neuilly-sur-Seine, France.
Eur J Hosp Pharm. 2023 Dec 27;31(1):79-81. doi: 10.1136/ejhpharm-2020-002605.
Coronavirus disease 2019 (COVID-19) has spread rapidly around the world. Like many clinical teams, hospital pharmacies have widely contributed in preventing and containing the COVID-19 pandemic. Pharmacies were thus involved in the management of overuse of specific drugs, medication shortages and risk of medication errors.
To assess the use of curares during the COVID-19 crisis and to highlight the lessons to be learnt from this overuse.
The use of curares (Atracurium, Cisatracurium and Rocuronium) was compared with the usual use levels in our hospital. Supply issues have been identified and investigated. The risk of medication errors was clearly established and considered.
Despite an increased demand, our hospital has not experienced any disruption in the supply of curare medications. But the risk of curare shortages has led to the registration of new pharmaceutical forms and dosages never used before. We also observed necessary switches between different curares. All of this has contributed to an increased risk of medication errors.
During the COVID-19 pandemic, the pharmaceutical management of curare medications has been particularly critical. The risk of medication errors and unsafe medication practices was high. This analysis must lead to a high level of vigilance in the next few months.
2019 年冠状病毒病（COVID-19）在全球迅速蔓延。与许多临床团队一样，医院药房在预防和控制 COVID-19 大流行方面做出了广泛贡献。因此，药房参与了对特定药物的过度使用、药物短缺和用药错误风险的管理。
评估 COVID-19 危机期间肌松剂的使用情况，并从这种过度使用中吸取教训。
比较了我院肌松剂（阿曲库铵、顺阿曲库铵和罗库溴铵）的使用情况与常规使用水平。已确定并调查了供应问题。明确并考虑了用药错误的风险。
尽管需求增加，但我院并未经历肌松剂供应中断。但肌松剂短缺的风险导致了新的药品剂型和从未使用过的剂量的注册。我们还观察到了不同肌松剂之间的必要转换。所有这些都增加了用药错误的风险。
在 COVID-19 大流行期间，肌松剂的药物管理尤为关键。用药错误和不安全用药的风险很高。这种分析必须在未来几个月内引起高度警惕。
